Abarceo Pharma AB

About:

Abarceo Pharma has identified a novel diabetes target located on beta cells and a novel mechanism of action enabling a therapeutic.

Website: https://www.abarceo.com

Top Investors: Almi Invest, LU Innovation

Description:

Abarceo Pharma is a spin out of Lund University Diabetes Center and is located in Malmo Sweden. Scientific founders Prof. Claes Wollheim, MD and Associate Prof. Albert Salehi are world-class experts in beta cell biology. Abarceo Pharma is a Lund University Holding company and was founded in December 2017. The company is dedicated to developing novel therapeutics for type-2 diabetes based upon a deep molecular and genetic understanding of the disease.